This part of our website is a set of studies of adverse reactions cases, published by the National Institutes of Health (U.S. Department of Health and Human Services) and American Library of Medicine (also operated by the United States federal government).

Due to amount of publications and a shortage of volunteers we can’t provide links to all publications. There are also multiple studies published in other medical databases, medical journals, and by consultant’s associations. All studies of adverse reactions published on PubMed can be found here.

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons, Moderna & Pfizer-BioNTech.

Small fiber neuropathy as a complication of SARS-CoV-2 vaccinations. Moderna. Austria.

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey. Pfizer-BioNTech. Japan.

Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience. Pfizer-BioNTech. Italy.

Anaphylaxis and Related Events Following COVID-19 Vaccination: A Systematic Review. Multipkle vaccines. Quatar.

Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States. Moderna & Pfizer-BioNtech. Greece.

Clinical and immunological data from chronic urticaria onset after mRNA SARS-CoV-2 vaccines. Moderna & Pfizer-BioNTech. Switzerland.

Sever erythema multiforme post-COVID-19 moderna vaccine: Case report and literature review. Moderna. Quatar.

Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: reports to the Vaccine Adverse Event Reporting System. Janssen. USA.

Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty^Ⓡ]). Pfizer-BioNTech, Japan.

Epidemiology and clinical features of myocarditis/pericarditis before the introduction of mRNA COVID-19 vaccine in Korean children: a multicenter study. Pfizer-BioNtech. Korea.

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. AstraZeneca. Norway & Denmark.

Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. Multiple vaccines. Columbia & USA.

Association of COVID-19 vaccination before conception with maternal liver function during early pregnancy: a cohort study of 7745 Chinese pregnant women. Multiple vaccines. China.

Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. Multiple vaccines. Italy.

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. AstraZeneca & Pfizer-BioNTech. UK.

Influence of COVID-19 vaccines on endocrine system. Multiple vaccines. China.

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Multiple vaccines. Spain.

Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study. Multiple vaccines. Norway.

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020. AstraZeneca. USA.

Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. Pfizer-BioNtech. USA.

Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure. Germany.

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Moderna & Pfizer-BioNtech. USA.

Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination. Moderna & Pfizer. USA

Purpuric rash and thrombocytopenia after mRNA-1273 (Moderna) COVID-19 vaccine. USA

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase

Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event. Singapore

The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination. AstraZeneca. Italy.

Thrombosis with thrombocytopenia after messenger RNA vaccine -1273. Multiple vaccines. USA

Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data. Pfizer-BionTech & AstraZeneca. Italy.

Exacerbation of immune thrombocytopenia after COVID-19 vaccination. Multiple vaccines. Italy.

First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine.Pfizer-BioNTech. Belgium.

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19. Pfizer-BioNTech. Spain.

COVID-19 mRNA vaccination and myocarditis. Pfizer-BioNTech. USA.

COVID-19 vaccine and myocarditis. Multiple vaccines. USA.

COVID-19 vaccines and myocarditis. Multiple vaccines. France.

Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination. Pfizer-BioNTech. Australia.

Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA. Pfizer-BioNTech. Korea.

The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism. Moderna & Pfizer-BionTech. Greece.

.

Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database. Multiple vaccines. USA.

Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis? AstraZeneca & Pfizer-BioNTech. Germany.

Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent. Pfizer-BioNTech. USA.

Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Pfizer-BioNTech. USA.

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report. Pfizer-BioNTech. USA

Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report. Pfizer-BioNTech. Germany

Myocarditis following mRNA COVID-19 vaccination: call for endomyocardial biopsy. Pfizer-BioNTech. Austria & Germany.

Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination. Moderna. Quatar.

Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship. Pfizer-BioNTech. Italy.

COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. Moderna. Germany.

COVID-19 vaccine induced rhabdomyolysis: Case report with literature review. Pfizer. USA.

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. Pfizer. USA

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. Pfizer–BioNTech. Israel & USA

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Moderna & Pfizer-BioNTech. USA.

Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US Regional Health System. Moderna & Pfizer-BioNTech. USA.

Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. Moderna. Japan.

Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Multiple vaccines. USA.

Perimyocarditis following COVID-19 vaccination. Pfizer-BioNTech. Portugal.

Fulminant necrotizing eosinophilic myocarditis after COVID-19 vaccination survived with mechanical circulatory support.Pfizer–BioNTech. Japan

Acute Myocarditis in a Patient Following mRNA-1273 SARS-CoV-2 Vaccination. Moderna. Japan.

Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine. Pfizer-BoiNTech. Israel.

Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? Moderna. Switzerland & UK.

Autoimmune hepatitis following vaccination for SARS-CoV-2 in Korea: coincidence or autoimmunity? Pfizer-BioNTech. Korea.

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. Moderna. Switzerland.

Graves’ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases. Multiple vaccines. UK.

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review. Multiple vaccines. Saudi Arabia, Pakistan, Malaysia & USA.

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. AstraZeneca & Pfizer-BioNTech. UK.

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). AstraZeneca. Spain.

Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine. Pfizer-BioNtech. Malaysia.

Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Janssen. Italy.

Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. Moderna. USA.

Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021. AsraZeneca &Pfizer-BioNTech. South Korea.

Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. Modserna & Pfizer-BioNTech. Germany, Switzerland, Spain, Poland & France.

Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Pfizer-BioNTech. Germany.

Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry. Moderna & Pfizer-BioNTech. USA

IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines. Moderna &Pfizer-BioNTech, USA

COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome, Astra Zeneca. Italy.

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. Astra Zeneca. Iran, USA & Canada.

Nervous and muscular adverse events after COVID-19 vaccination: a systematic review and Meta-Analysis of clinical trials. Multiple vaccines. China.

A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration. Astra Zeneca. Italy

Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration. Astra Zeneca, France.

Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines. Moderna & Pfizer-BioNTech. USA.

Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Multiple vaccines. Israel.

Acute transverse myelitis (ATM):clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Astra Zeneca. USA & Panama.

Acute abducens nerve palsy following COVID-19 vaccination. Pfizer-BioNTech. USA.

Thrombosis of the palmar digital vein after Oxford-AstraZeneca COVID-19 vaccination. Astra Zeneca. Taiwan.

[Lipschütz Ulcers After the AstraZeneca COVID-19 Vaccine]. Astra Zeneca. Spain.

Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism. Astra Zeneca & Janssen. Poland.

Coronavirus (COVID-19) vaccine-induced immune thrombotic thrombocytopenia (VITT). Multiple vaccines. USA

Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. Astra Zeneca. Canada.

Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature.Astra Zeneca. Italy.

Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia. Multiple vaccines. Korea.

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. Pfizer-BioNTech. Israel.

Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2-Vaccination in vaccine induced thrombotic thrombocytopenia-VITT. Multiple vaccines. USA & Germany.

Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST). Astra Zeneca. Saudi Arabia.

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. Astra Zeneca. Australia.

The International Cerebral Venous Thrombosis Consortium report on cerebral venous thrombosis following vaccination against SARS-CoV-2. Multiple vaccines. UK.

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. Astra Zeneca. Denmark & Norway.

Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. Astra Zeneca & Jenssen. Australia.

Predicted and observed incidence .of thromboembolic events among Koreans vaccinated with ChAdOx1 nCoV-19 Vaccine. Astra Zeneca. South Korea.

Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Multiple vaccines. Jordan.

COVID-19 vaccination-associated myocarditis in adolescents. Multiple vaccines. USA.